Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis

References

• Farrell P, Férec C, Macek M, et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. Eur J Hum Genet. 2018;26(12):1832–1839. doi: 10.1038/s41431-018-0234-z
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Trust. UK Cystic Fibrosis Registry 2021 Annual Data Report: Cystic Fibrosis Trust; 2022. [cited Sep 2022]. Available from: https://www.cysticfibrosis.org.uk/sites/default/files/2022-10/CFT_2021-Annual-Data-Report-WEB.pdf.
   Google Scholar
• Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child. 1938;56(2):344–399. doi: 10.1001/archpedi.1938.01980140114013
   Google Scholar
• Wilmers MJ, Mackay HM, Anderson IM. Five cases of cystic fibrosis of the pancreas. Proc R Soc Med. 1950;43(11):829–832.
   PubMedGoogle Scholar
• Andersen DH. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics. 1949;3(4):406–417. doi: 10.1542/peds.3.4.406
   PubMed Web of Science ®Google Scholar
• Sathe M, Houwen R. Meconium ileus in cystic fibrosis. J Cyst Fibros. 2017;16:S32–S9. doi: 10.1016/j.jcf.2017.06.007
   PubMedGoogle Scholar
• Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr Surg. 2012;47(4):772–781. doi: 10.1016/j.jpedsurg.2012.02.019
   PubMed Web of Science ®Google Scholar
• Rowbotham NJ, Smith S, Leighton PA, et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax. 2018;73(4):388–390. doi: 10.1136/thoraxjnl-2017-210473
   PubMed Web of Science ®Google Scholar
• Rowbotham NJ, Smith S, Elliott ZC, et al. A refresh of the top 10 research priorities in cystic fibrosis. Thorax. 2023:thorax-2023–220100. doi: 10.1136/thorax-2023-220100
   Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. NEJM. 2011;365(18):1663–1672. doi: 10.1056/NEJMoa1105185
   PubMed Web of Science ®Google Scholar
• Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. NEJM. 2019;381(19):1809–1819. doi: 10.1056/NEJMoa1908639
   PubMed Web of Science ®Google Scholar
• Nichols AL, Davies JC, Jones D, Carr SB, et al. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev. 2020;35:99–102. doi: 10.1016/j.prrv.2020.04.003
   PubMed Web of Science ®Google Scholar
• Munce D, Lim M, Akong K. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Pediatr Pulmonol. 2020;55(12):3381–3383. doi: 10.1002/ppul.25065
   PubMed Web of Science ®Google Scholar
• Megalaa R, Gopalareddy V, Champion E, et al. Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use. Pediatr Pulmonol. 2019;54(8):E16–E8. doi: 10.1002/ppul.24353
   PubMed Web of Science ®Google Scholar
• Hamilton JL, Zobell JT, Robson J. Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor. Pediatr Pulmonol. 2019;54(11):1654–. doi: 10.1002/ppul.24454
   PubMed Web of Science ®Google Scholar
• Smith H, Rayment JH. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor. Pediatr Pulmonol. 2020;55(10):2493–2494. doi: 10.1002/ppul.24952
   PubMed Web of Science ®Google Scholar
• Hutchinson I, Mcnally P. Appearance of pancreatic sufficiency and discontinuation of pancreatic enzyme replacement therapy in children with cystic fibrosis on ivacaftor. Ann Am Thorac Soc. 2021;18(1):182–183. doi: 10.1513/AnnalsATS.202006-614RL
   PubMed Web of Science ®Google Scholar
• Davies JC, Cunningham S, Harris W, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107–115. doi: 10.1016/S2213-2600(15)00545-7
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Cunningham S, T HW, et al. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros. 2019;18(6):838–843. doi: 10.1016/j.jcf.2019.03.009
   PubMed Web of Science ®Google Scholar
• Mainz JG, Zagoya C, Polte L, et al. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained with the CF-Specific CFAbd-Score. Front Pharmacol. 2022;13. doi: 10.3389/fphar.2022.877118
   PubMed Web of Science ®Google Scholar
• Rowbotham NJ, Smith S, Prayle AP, et al. Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review. Thorax. 2019;74(3):229–236. doi: 10.1136/thoraxjnl-2017-210858
   PubMed Web of Science ®Google Scholar
• Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane rapid reviews methods group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13–22. doi: 10.1016/j.jclinepi.2020.10.007
   PubMed Web of Science ®Google Scholar
• Smith S, Rowbotham N, Davies G, et al. How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respir Res. 2020;7(1):e000614. doi: 10.1136/bmjresp-2020-000614
   PubMed Web of Science ®Google Scholar
• Caley LR, White H, de Goffau MC, et al. Cystic fibrosis-related gut dysbiosis: a systematic review. Dig Dis Sci. 2023;68(5):1797–1814. doi: 10.1007/s10620-022-07812-1
   PubMedGoogle Scholar
• Dimango E, Walker P, Keating C, et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med. 2014;14(1):21. doi: 10.1186/1471-2466-14-21
   PubMedGoogle Scholar
• Garg M, Leach ST, Coffey MJ, et al. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros. 2017;16(5):631–636. doi: 10.1016/j.jcf.2017.03.010
   PubMed Web of Science ®Google Scholar
• Pauwels A, Verleden S, Farre R, et al. The effect of gastric juice on interleukin-8 production by cystic fibrosis primary bronchial epithelial cells. J Cyst Fibros. 2013;12(6):700–705. doi: 10.1016/j.jcf.2013.03.006
   PubMed Web of Science ®Google Scholar
• Engjom T, Erchinger F, Tjora E, et al. Diagnostic accuracy of secretin-stimulated ultrasonography of the pancreas assessing exocrine pancreatic failure in cystic fibrosis and chronic pancreatitis. Scand J Gastroenterol. 2015;50(5):601–610. doi: 10.3109/00365521.2015.1004363
   PubMed Web of Science ®Google Scholar
• Hite MA, Gaertner WB, Garcia B, et al. Abdominal Surgical Procedures in Adult Patients with Cystic Fibrosis: what are the Risks? Dis Colon Rectum. 2022;65(8):e805–e15. doi: 10.1097/DCR.0000000000002162
   PubMed Web of Science ®Google Scholar
• Sharma A, Morton A, Peckham D, et al. Gastrointestinal surgery in adult patients with cystic fibrosis. Frontline Gastroenterol. 2012;3(4):242–247. doi: 10.1136/flgastro-2012-100184
   PubMedGoogle Scholar
• Van Biervliet S, Declercq D, Somerset S. Clinical effects of probiotics in cystic fibrosis patients: a systematic review. Clin Nutr ESPEN. 2017;18:37–43. doi: 10.1016/j.clnesp.2017.01.007
   PubMedGoogle Scholar
• Nikniaz Z, Nikniaz L, Bilan N, et al. Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials. World J Pediatr. 2017;13(4):307–313. doi: 10.1007/s12519-017-0033-6
   PubMed Web of Science ®Google Scholar
• Neri LDCL, Taminato M, Silva Filho LVRFD. Systematic review of probiotics for cystic fibrosis patients: moving forward. J Pediatr Gastroenterol Nutr. 2019;68(3):394–399. doi: 10.1097/MPG.0000000000002185
   PubMed Web of Science ®Google Scholar
• Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: a systematic review. J Cyst Fibros. 2017;16(2):186–197. doi: 10.1016/j.jcf.2016.09.004
   PubMed Web of Science ®Google Scholar
• Bongiovanni A, Manti S, Parisi GF, et al. Focus on gastroesophageal reflux disease in patients with cystic fibrosis. World J Gastroenterol. 2020;26(41):6322–6334. doi: 10.3748/wjg.v26.i41.6322
   PubMed Web of Science ®Google Scholar
• Imrei M, Németh D, Szakács Z, et al. Increased prevalence of celiac disease in patients with cystic fibrosis: a systematic review and meta-analysis. J Pers Med. 2021;11(9):859. doi: 10.3390/jpm11090859
   PubMed Web of Science ®Google Scholar
• Gilchrist FJ, Green J, Carroll W. Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018;8(8):Cd012798. doi: 10.1002/14651858.CD012798.pub2
   PubMedGoogle Scholar
• Stefano MA, Poderoso RE, Mainz JG, et al. Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies. J Pediatr (Rio J). 2020;96(6):686–692. doi: 10.1016/j.jped.2020.03.004
   PubMed Web of Science ®Google Scholar
• Yamada A, Komaki Y, Komaki F, et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):758–767. doi: 10.1016/S1470-2045(18)30188-8
   PubMed Web of Science ®Google Scholar
• Shinar S, Agrawal S, Ryu M, et al. Fetal meconium peritonitis - prenatal findings and postnatal outcome: a case series systematic review, and meta-analysis. Ultraschall Med. 2022;43(2):194–203. doi: 10.1055/a-1194-4363
   PubMedGoogle Scholar
• Ng SM, Franchini AJ. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2021;2014(7):Cd003424.
   Google Scholar
• Pauwels A, Blondeau K, Dupont JL, et al. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol. 2012;107(9):1346–1353. doi: 10.1038/ajg.2012.213
   PubMed Web of Science ®Google Scholar
• Mendez BM, Davis CS, Weber C, et al. Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis. Am J Surg. 2012;204(5):e21–6. doi: 10.1016/j.amjsurg.2012.07.019
   PubMed Web of Science ®Google Scholar
• Hauser B, De Schepper J, Malfroot A, et al. Gastric emptying and gastro-oesophageal reflux in children with cystic fibrosis. J Cyst Fibros. 2016;15(4):540–547. doi: 10.1016/j.jcf.2015.12.015
   PubMed Web of Science ®Google Scholar
• Ng C, Dellschaft NS, Hoad CL, et al. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. J Cyst Fibros. 2021;20(4):591–597. doi: 10.1016/j.jcf.2020.06.004
   PubMed Web of Science ®Google Scholar
• Safe M, Cho J, Krishnan U. Combined multichannel intraluminal impedance and pH measurement in detecting gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2016;63(5):e98–e106. doi: 10.1097/MPG.0000000000001396
   PubMed Web of Science ®Google Scholar
• Gelfond D, Ma C, Semler J, et al. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 2013;58(8):2275–2281. doi: 10.1007/s10620-012-2209-1
   PubMed Web of Science ®Google Scholar
• Hedsund C, Gregersen T, Joensson IM, et al. Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol. 2012;47(8–9):920–926. doi: 10.3109/00365521.2012.699548
   PubMed Web of Science ®Google Scholar
• Kokubo T, Matsui S, Ishiguro M. Meta-analysis of oro-cecal transit time in fasting subjects. Pharm Res. 2013;30(2):402–411. doi: 10.1007/s11095-012-0882-6
   PubMed Web of Science ®Google Scholar
• Spiller RC, Trotman IF, Adrian TE, et al. Further characterisation of the ‘ileal brake’ reflex in man–effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut. 1988;29(8):1042–1051. doi: 10.1136/gut.29.8.1042
   PubMed Web of Science ®Google Scholar
• Wen J, Phillips SF, Sarr MG, et al. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol. 1995;269(6 Pt 1):G945–52. doi: 10.1152/ajpgi.1995.269.6.G945
   PubMedGoogle Scholar
• Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–s9. doi: 10.1016/j.jcf.2017.06.013
   PubMedGoogle Scholar
• Deiteren A, Camilleri M, Burton D, et al. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci. 2010;55(2):384–391. doi: 10.1007/s10620-009-1041-8
   PubMed Web of Science ®Google Scholar
• Coffin B, Lémann M, Flourié B, et al. Ileal tone in humans: effects of locoregional distensions and eating. Am J Physiol. 1994;267(4 Pt 1):G569–74. doi: 10.1152/ajpgi.1994.267.4.G569
   PubMedGoogle Scholar
• Marsh R, Gavillet H, Hanson L, et al. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. J Cyst Fibros. 2022;21(3):506–513. doi: 10.1016/j.jcf.2021.11.014
   PubMedGoogle Scholar
• Knudsen PK, Brandtzaeg P, Høiby EA, et al. Impact of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in children in a low resistance prevalence setting. PLoS One. 2017;12(11):e0187618. doi: 10.1371/journal.pone.0187618
   PubMed Web of Science ®Google Scholar
• Burke DG, Harrison MJ, Fleming C, et al. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2017;16(2):291–298. doi: 10.1016/j.jcf.2016.09.008
   PubMed Web of Science ®Google Scholar
• Deane J, Fouhy F, Ronan NJ, et al. A multicentre analysis of Clostridium difficile in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level. J Infect. 2021;82(3):363–370. doi: 10.1016/j.jinf.2020.12.027
   PubMed Web of Science ®Google Scholar
• Enaud R, Hooks KB, Barre A, et al. Intestinal Inflammation in Children with Cystic Fibrosis is Associated with Crohn’s-Like Microbiota Disturbances. J Clin Med. 2019;8(5):645. doi: 10.3390/jcm8050645
   PubMed Web of Science ®Google Scholar
• Furnari M, De Alessandri A, Cresta F, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–270. doi: 10.1007/s00535-018-1509-4
   PubMed Web of Science ®Google Scholar
• Ronan NJ, Einarsson GG, Deane J, et al. Modulation, microbiota and inflammation in the adult CF gut: a prospective study. J Cyst Fibros. 2022;21(5):837–843. doi: 10.1016/j.jcf.2022.06.002
   PubMed Web of Science ®Google Scholar
• Adriaanse MP, Van Der Sande LJTM, Van Den Neucker AM, et al. Evidence for a Cystic Fibrosis Enteropathy. PLoS One. 2015;10(10):e0138062. doi: 10.1371/journal.pone.0138062
   PubMed Web of Science ®Google Scholar
• Jaudszus A, Pfeifer E, Lorenz M, et al. Abdominal symptoms assessed with the CFAbd-score are associated with intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2022;74(3):355–360. doi: 10.1097/MPG.0000000000003357
   PubMed Web of Science ®Google Scholar
• Dhaliwal J, Leach S, Katz T, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60(4):521–526. doi: 10.1097/MPG.0000000000000683
   PubMed Web of Science ®Google Scholar
• Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014;9(2):e87796. doi: 10.1371/journal.pone.0087796
   PubMed Web of Science ®Google Scholar
• Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20(7):813–819. doi: 10.1111/j.1365-2036.2004.02174.x
   PubMed Web of Science ®Google Scholar
• Ellemunter H, Engelhardt A, Schüller K, et al. Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years. J Pediatr Gastroenterol Nutr. 2017;65(4):438–442. doi: 10.1097/MPG.0000000000001544
   PubMed Web of Science ®Google Scholar
• Roda J, Maia C, Almeida S, et al. Faecal calprotectin and rectal histological inflammatory markers in cystic fibrosis: a single-centre study. BMJ Paediatr Open. 2022;6(1):e001422. doi: 10.1136/bmjpo-2022-001422
   PubMedGoogle Scholar
• Stallings VA, Sainath N, Oberle M, et al. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations. J Pediatr. 2018;201:229–37.e4. doi: 10.1016/j.jpeds.2018.05.018
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Huang R, Heltshe SL, et al. Association between stool consistency and clinical variables among infants with cystic fibrosis: findings from the BONUS study. J Cyst Fibros. 2022;21(5):830–836. doi: 10.1016/j.jcf.2022.05.003
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Baccarin A, Corti F, et al. Bowel ultrasound imaging in patients with cystic fibrosis: relationship with clinical symptoms and CFTR genotype. Dig Liver Dis. 2016;48(3):271–276. doi: 10.1016/j.dld.2015.09.010
   PubMedGoogle Scholar
• Woodley FW, Machado RS, Hayes D, et al. Children with cystic fibrosis have prolonged chemical clearance of acid reflux compared to symptomatic children without cystic fibrosis. Dig Dis Sci. 2014;59(3):623–630. doi: 10.1007/s10620-013-2950-0
   PubMed Web of Science ®Google Scholar
• De Sillos MD, Chiba SM, Soares AC, et al. Colonic Transit Time and Fecal Impaction in Children and Adolescents with Cystic Fibrosis-associated Constipation. J Pediatr Gastroenterol Nutr. 2021;73(3):319–324. doi: 10.1097/MPG.0000000000003202
   PubMed Web of Science ®Google Scholar
• Olsen MF, Kjøller-Svarre MS, Møller G, et al. Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: results of a Cross-Sectional Study. Nutrients. 2022;14(7):1330. doi: 10.3390/nu14071330
   PubMed Web of Science ®Google Scholar
• Ramos AF, de Fuccio MB, Moretzsohn LD, et al. Cystic fibrosis, gastroduodenal inflammation, duodenal ulcer, and H. pylori infection: the “cystic fibrosis paradox” revisited. J Cyst Fibros. 2013;12(4):377–383. doi: 10.1016/j.jcf.2012.11.001
   PubMed Web of Science ®Google Scholar
• Subhi R, Ooi R, Finlayson F, et al. Distal intestinal obstruction syndrome in cystic fibrosis: presentation, outcome and management in a tertiary hospital (2007-2012). ANZ J Surg. 2014;84(10):740–744. doi: 10.1111/ans.12397
   PubMed Web of Science ®Google Scholar
• Raun AM, Brekke G, Mølgaard C, et al. Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF. Acta Paediatr. 2022;111(2):432–439. doi: 10.1111/apa.16143
   PubMed Web of Science ®Google Scholar
• Munck A, Alberti C, Colombo C, et al. International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: associated factors and outcome. J Cyst Fibros. 2016;15(4):531–539. doi: 10.1016/j.jcf.2016.02.002
   PubMed Web of Science ®Google Scholar
• Malagelada C, Bendezú RA, Seguí S, et al. Motor dysfunction of the gut in cystic fibrosis. Neurogastroenterol Motil. 2020;32(9):e13883. doi: 10.1111/nmo.13883
   PubMed Web of Science ®Google Scholar
• Anderson JL, Tierney AC, Miles C, et al. Probiotic use in adults with cystic fibrosis is common and influenced by gastrointestinal health needs: a cross-sectional survey study. J Hum Nutr Diet. 2022;35(3):444–454. doi: 10.1111/jhn.12991
   PubMed Web of Science ®Google Scholar
• Banjar H, Bawazir A, Ghomraoui F, et al. The first report on the association of celiac disease and cystic fibrosis in a tertiary care center in Saudi Arabia. Int J Pediatr Adolesc Med. 2022;9(1):56–61. doi: 10.1016/j.ijpam.2021.05.001
   PubMedGoogle Scholar
• Shah N, Tan HL, Sebire N, et al. The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients. Pediatr Pulmonol. 2013;48(12):1181–1189. doi: 10.1002/ppul.22697
   PubMed Web of Science ®Google Scholar
• Farjadian S, Moghtaderi M, Kashef S, et al. Clinical and genetic features in patients with cystic fibrosis in southwestern iran. Iran J Pediatr. 2013;23(2):212–215.
   PubMed Web of Science ®Google Scholar
• Sathe M, Huang R, Heltshe S, et al. Gastrointestinal factors associated with hospitalization in infants with cystic fibrosis: results from the baby observational and nutrition study. J Pediatr Gastroenterol Nutr. 2021;73(3):395–402. doi: 10.1097/MPG.0000000000003173
   PubMed Web of Science ®Google Scholar
• Ooi CY, Jeyaruban C, Lau J, et al. High ambient temperature and risk of intestinal obstruction in cystic fibrosis. J Paediatr Child Health. 2016;52(4):430–435. doi: 10.1111/jpc.13096
   PubMed Web of Science ®Google Scholar
• Coutinho CA, Marson FA, Ribeiro AF, et al. Cystic fibrosis transmembrane conductance regulator mutations at a referral center for cystic fibrosis. J Bras Pneumol. 2013;39(5):555–561. doi: 10.1590/S1806-37132013000500005
   PubMed Web of Science ®Google Scholar
• Farahmand F, Tajdini P, Falahi G, et al. Evaluation of serum adenosine deaminase in cystic fibrosis patients in an Iranian Referral Hospital. Innov J Pediatr. 2016;26(3):e2246. doi: 10.5812/ijp.2246v3
   Web of Science ®Google Scholar
• Toth T, Mak E, Galio N, et al. Research on the quality of life of adult patients with cystic fibrosis in Hungary. New Med. 2016;20:53–58. doi: 10.5604/14270994.1206757
   Google Scholar
• Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393–407.e5. doi: 10.1053/j.gastro.2016.02.031
   Web of Science ®Google Scholar
• Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130(5):1527–1537. doi: 10.1053/j.gastro.2005.08.063
   PubMed Web of Science ®Google Scholar
• Dellschaft NS, Ng C, Hoad C, et al. Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls. J Cyst Fibros. 2022;21(3):502–505. doi: 10.1016/j.jcf.2021.12.007
   PubMedGoogle Scholar
• Al-Baba R, Zetoune AB. A retrospective study of cases diagnosed with cystic fibrosis at a single care center in syria. Egypt J Med Hum Genet. 2021;22(1):59. doi: 10.1186/s43042-021-00178-5
   Google Scholar
• Sağlam D, Demirbaş F, Bilgici MC, et al. Can point shear wave elastography be used as an early indicator of involvement? J Ultrasound Med. 2020;39(9):1769–1776. doi: 10.1002/jum.15281
   PubMed Web of Science ®Google Scholar
• Aziz DA, Billoo AG, Qureshi A, et al. Clinical and laboratory profile of children with Cystic Fibrosis: experience of a tertiary care center in Pakistan. Pak J Med Sci. 2017;33(3):554–559. doi: 10.12669/pjms.333.12188
   PubMed Web of Science ®Google Scholar
• Caldaro T, Alghisi F, De Angelis P, et al. Cystic fibrosis: a surgical matter? J Pediatr Surg. 2014;49(5):753–758. doi: 10.1016/j.jpedsurg.2014.02.089
   PubMed Web of Science ®Google Scholar
• Huang L, Lai HJ, Antos N, et al. Defining and identifying early-onset lung disease in cystic fibrosis with cumulative clinical characteristics. Pediatr Pulmonol. 2022;57(10):2363–2373. doi: 10.1002/ppul.26040
   PubMed Web of Science ®Google Scholar
• Kristensen M, Prevaes S, Kalkman G, et al. Development of the gut microbiota in early life: the impact of cystic fibrosis and antibiotic treatment. J Cyst Fibros. 2020;19(4):553–561. doi: 10.1016/j.jcf.2020.04.007
   PubMed Web of Science ®Google Scholar
• Baad M, Delgado J, Dayneka JS, et al. Diagnostic performance and role of the contrast enema for low intestinal obstruction in neonates. Pediatr Surg Int. 2020;36(9):1093–1101. doi: 10.1007/s00383-020-04701-4
   PubMed Web of Science ®Google Scholar
• Farrelly PJ, Charlesworth C, Lee S, et al. Gastrointestinal surgery in cystic fibrosis: a 20-year review. J Pediatr Surg. 2014;49(2):280–283. doi: 10.1016/j.jpedsurg.2013.11.038
   PubMed Web of Science ®Google Scholar
• Rafeey M, Jabarpoor-Bonyadi M, Vahedi L. Genotype-phenotype correlation for cystic fibrosis according to registry center of cystic fibrosis. Crescent J Med Biol Sci. 2020;7(1):124–129.
   Google Scholar
• Beaufils F, Mas E, Mittaine M, et al. Increased fecal calprotectin is associated with worse gastrointestinal symptoms and quality of life scores in children with cystic fibrosis. J Clin Med. 2020;9(12):4080. doi: 10.3390/jcm9124080
   PubMed Web of Science ®Google Scholar
• Mentessidou A, Loukou I, Kampouroglou G, et al. Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises. J Pediatr Surg. 2018;53(8):1504–1508. doi: 10.1016/j.jpedsurg.2017.11.040
   PubMed Web of Science ®Google Scholar
• Guo X, Pace RG, Stonebraker JR, et al. Meconium ileus in cystic fibrosis is not linked to central repetitive region length variation in MUC1, MUC2, and MUC5AC. J Cyst Fibros. 2014;13(6):613–616. doi: 10.1016/j.jcf.2014.05.005
   PubMed Web of Science ®Google Scholar
• Smith DJ, Klein K, Hartel G, et al. Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene. 2019;683:12–17. doi: 10.1016/j.gene.2018.10.002
   PubMed Web of Science ®Google Scholar
• Thomas L, Kumar M, Lionel BA, et al. Pancreatic, hepatobiliary, and gastrointestinal manifestations of children with cystic fibrosis: a 10-year experience from a tertiary care center in southern India. Indian J Gastroenterol. 2022;41(3):266–272. doi: 10.1007/s12664-021-01225-0
   PubMed Web of Science ®Google Scholar
• Aksit MA, Ling H, Pace RG, et al. Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis. Am J Hum Genet. 2022;109(10):1894–1908. doi: 10.1016/j.ajhg.2022.09.004
   PubMed Web of Science ®Google Scholar
• Banjar H, Qeretli R, Ramadan A, et al. The first report on CFTR mutations of meconium ileus in cystic fibrosis population in Saudi Arabia: a single center review. Int J Pediatr Adolesc Med. 2022;9(1):32–35. doi: 10.1016/j.ijpam.2021.03.008
   PubMedGoogle Scholar
• Terlizzi V, Carnovale V, Castaldo G, et al. Clinical expression of patients with the D1152H CFTR mutation. J Cyst Fibros. 2015;14(4):447–452. doi: 10.1016/j.jcf.2014.12.012
   PubMed Web of Science ®Google Scholar
• Kumar A, Aggarwal B, Bamal P, et al. Clinical profile of children with cystic fibrosis surviving through adolescence and beyond. Indian Pediatr. 2022;59(1):43–45. doi: 10.1007/s13312-022-2419-3
   PubMed Web of Science ®Google Scholar
• Rovner AJ, Schall JI, Mondick JT, et al. Delayed small bowel transit in children with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr. 2013;57(1):81–84. doi: 10.1097/MPG.0b013e318290d112
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Keivanfar M, Navaei S, et al. First cystic fibrosis patient registry annual data report - cystic fibrosis foundation of Iran. Acta Med Iran. 2019;57(1):33–41. doi: 10.18502/acta.v57i1.1751
   Google Scholar
• Declercq D, Van Biervliet S, Robberecht E. Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome. Nutr Clin Pract. 2015;30(1):134–137. doi: 10.1177/0884533614551838
   PubMed Web of Science ®Google Scholar
• Gabel ME, Wang H, Gelfond D, et al. Changes in glucose breath test in cystic fibrosis patients treated with 1 month of lumacaftor/ivacaftor. J Pediatr Gastroenterol Nutr. 2022;75(1):42–47. doi: 10.1097/MPG.0000000000003459
   PubMed Web of Science ®Google Scholar
• Ooi CY, Pang T, Leach ST, et al. Fecal human β-defensin 2 in children with cystic fibrosis: is there a diminished intestinal innate immune response? Dig Dis Sci. 2015;60(10):2946–2952. doi: 10.1007/s10620-015-3842-2
   PubMed Web of Science ®Google Scholar
• Del Campo R, Garriga M, Pérez-Aragón A, et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros. 2014;13(6):716–722. doi: 10.1016/j.jcf.2014.02.007
   PubMed Web of Science ®Google Scholar
• Bozic M, Goss CH, Tirouvanziam RM et al. Oral Glutathione and Growth in Cystic Fibrosis: a Multicenter, Randomized, Placebo-controlled, Double-blind Trial. J Pediatr Gastroenterol Nutr. 2020;71(6):771–777. doi: 10.1097/MPG.0000000000002948
   PubMed Web of Science ®Google Scholar
• Tétard C, Mittaine M, Bui S, et al. Reduced intestinal inflammation with lumacaftor/ivacaftor in adolescents with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2020;71(6):778–781. doi: 10.1097/MPG.0000000000002864
   PubMed Web of Science ®Google Scholar
• Shakir S, Echevarria C, Doe S, et al. Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. 2022;21(5):807–810. doi: 10.1016/j.jcf.2022.06.003
   PubMed Web of Science ®Google Scholar
• Woodley FW, Hayes Jr D, Kopp BT, et al. Gastroesophageal reflux in cystic fibrosis across the age spectrum. Transl Gastroenterol Hepatol. 2019;4:69. doi: 10.21037/tgh.2019.08.11
   PubMed Web of Science ®Google Scholar
• Brecelj J, Zidar N, Jeruc J, et al. Morphological and functional assessment of oesophageal mucosa integrity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2016;62(5):757–764. doi: 10.1097/MPG.0000000000001131
   PubMed Web of Science ®Google Scholar
• Doumit M, Krishnan U, Jaffé A, et al. Acid and non-acid reflux during physiotherapy in young children with cystic fibrosis. Pediatr Pulmonol. 2012;47(2):119–124. doi: 10.1002/ppul.21524
   PubMed Web of Science ®Google Scholar
• Calvo-Lerma J, Martínez-Barona S, Masip E, et al. Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption. Rev Esp Enferm Dig. 2017;109(10):684–689. doi: 10.17235/reed.2017.4951/2017
   PubMed Web of Science ®Google Scholar
• Matson AG, Bunting JP, Kaul A, et al. A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterol. 2019;19(1):89. doi: 10.1186/s12876-019-0979-z
   PubMedGoogle Scholar
• Maisonneuve P, Marshall BC, Knapp EA, et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122–129. doi: 10.1093/jnci/djs481
   PubMedGoogle Scholar
• Billings JL, Dunitz JM, Mcallister S, et al. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol. 2014;48(9):e85–8. doi: 10.1097/MCG.0000000000000034
   PubMed Web of Science ®Google Scholar
• Schmedding A, Hutter M, Gfroerer S, et al. Jejunoileal atresia: a national cohort study. Front Pediatr. 2021;9:665022. doi: 10.3389/fped.2021.665022
   PubMed Web of Science ®Google Scholar
• Siersma CL, Rottier BL, Hulscher JB, et al. Jejunoileal atresia and cystic fibrosis: don’t miss it. BMC Res Notes. 2012;5:677. doi: 10.1186/1756-0500-5-677
   PubMedGoogle Scholar
• Emiralioglu N, Ademhan Tural D, Hizarcioglu Gulsen H, et al. Does cystic fibrosis make susceptible to celiac disease? Eur J Pediatr. 2021;180(9):2807–2813. doi: 10.1007/s00431-021-04011-4
   PubMed Web of Science ®Google Scholar
• Saxby NPC, Kench A, King S, et al. Nutrition Guidelines For Cystic Fibrosis In Australia And New Zealand Thoracic Society Of Australia And New Zealand, Sydney; 2017
   Google Scholar
• CF Trust Nutrition Working Group. Nutritional management of cystic fibrosis: cystic fibrosis trust; 2016. Available from: https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/Nutritional%20Management%20of%20cystic%20fibrosis%20Sep%2016.pdf.
   Google Scholar
• Smyth RL, Smyth AR, Lloyd DA et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet. 1994;343(8889):85–86. doi: 10.1016/S0140-6736(94)90817-6
   PubMed Web of Science ®Google Scholar
• Smyth RL, O’hea U, Burrows E, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet. 1995;346(8985):1247–1251. doi: 10.1016/S0140-6736(95)91860-4
   PubMed Web of Science ®Google Scholar
• Dodge JA. Pancreatic enzymes and fibrosing colonopathy. J Cyst Fibros. 2015;14(1):153. doi: 10.1016/j.jcf.2014.09.002
   PubMed Web of Science ®Google Scholar
• Gelfond D, Heltshe SL, Skalland M, et al. Pancreatic enzyme replacement therapy use in infants with cystic fibrosis diagnosed by newborn screening. J Pediatr Gastroenterol Nutr. 2018;66(4):657–663. doi: 10.1097/MPG.0000000000001829
   PubMed Web of Science ®Google Scholar
• Kashirskaya NY, Kapranov NI, Sander-Struckmeier S, et al. Safety and efficacy of Creon Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2015;14(2):275–281. doi: 10.1016/j.jcf.2014.07.006
   PubMed Web of Science ®Google Scholar
• Dodge JA. Fibrosing colonopathy. Gut. 2000;46(2):152–153. doi: 10.1136/gut.46.2.152
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines. Report of the pancreatic enzymes working party. Stationary Office: London; 1995.
   Google Scholar
• Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2021 annual data report. Bethesda (MD): Cystic Fibrosis Foundation; 2022.
   Google Scholar
• Knotts RM, Solfisburg QS, Keating C, et al. Cystic fibrosis is associated with an increased risk of Barrett’s esophagus. J Cyst Fibros. 2019;18(3):425–429. doi: 10.1016/j.jcf.2018.11.005
   PubMed Web of Science ®Google Scholar
• Davies JC, Alton EWFW, Bush A. Cystic fibrosis. BMJ. 2007;335(7632):1255–1259. doi: 10.1136/bmj.39391.713229.AD
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Exocrine pancreatic insufficiency; 2023. Available from: https://bnf.nice.org.uk/treatment-summaries/exocrine-pancreatic-insufficiency/#related-drugs.
   Google Scholar
• Ng C, Major G, Smyth AR. Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database Syst Rev. 2021;2021(8). doi: 10.1002/14651858.CD013488.pub2
   Google Scholar
• Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35(3):557–577. doi: 10.1016/j.clnu.2016.03.004
   PubMed Web of Science ®Google Scholar
• Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(6, Supplement):S73–S93. doi: 10.1016/j.jpeds.2009.09.001
   PubMed Web of Science ®Google Scholar
• Boon M, Calvo-Lerma J, Claes I, et al. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with cystic fibrosis. J Cyst Fibros. 2020;19(4):562–568. doi: 10.1016/j.jcf.2020.04.001
   PubMed Web of Science ®Google Scholar
• Doligalski CT, McKinzie CJ, Yang A, et al. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients. Pharmacotherapy. 2022;42(7):580–584. doi: 10.1002/phar.2710
   PubMed Web of Science ®Google Scholar
• Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81. doi: 10.1038/ctg.2017.10
   PubMedGoogle Scholar
• Pope CE, Vo AT, Hayden HS, et al. Changes in fecal microbiota with CFTR modulator therapy: a pilot study. J Cyst Fibros. 2021;20(5):742–746. doi: 10.1016/j.jcf.2020.12.002
   PubMed Web of Science ®Google Scholar
• Graeber SY, Dopfer C, Naehrlich L, et al. Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in phe508del homozygous patients with cystic fibrosis. Am J Respir Crit Care Med. 2018;197(11):1433–1442. doi: 10.1164/rccm.201710-1983OC
   PubMed Web of Science ®Google Scholar
• Smyth AR, Giles M Gut imaging for function and transit in cystic fibrosis study 2 (GIFT-CF2) clinicaltrials.Gov: clinicaltrials.Gov; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04006873.
   Google Scholar
• Smyth AR CFTR Modulators and Gastrointestinal Complications (CFTR-MAGIC) clinicaltrials.Gov: clinicaltrials.Gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05253859.
   Google Scholar
• Padoan R, Cirilli N, Falchetti D, et al. Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicentre Italian study. J Cyst Fibros. 2019;18(6):863–868. doi: 10.1016/j.jcf.2019.07.003
   PubMed Web of Science ®Google Scholar
• Abu-El-Haija M, Uc A, Werlin SL, et al. Nutritional considerations in pediatric pancreatitis: a position paper from the NASPGHAN pancreas committee and ESPGHAN Cystic Fibrosis/Pancreas Working Group. J Pediatr Gastroenterol Nutr. 2018;67(1):131–143. doi: 10.1097/MPG.0000000000002023
   PubMed Web of Science ®Google Scholar
• Jaudszus A, Zeman E, Jans T, et al. Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-score). Patient. 2019;12(4):419–428. doi: 10.1007/s40271-019-00361-2
   PubMedGoogle Scholar
• Smyth AR A comprehensive approach to relief of digestive symptoms in cystic fibrosis: CARDS-CF (CARDS-CF) clinicaltrials.Gov: clinicaltrials.Gov; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT05251467.
   Google Scholar
• Smyth AR The core outcome set taskforce for CF (COST-CF) comet initiative: comet initiative; 2022. Available from: https://www.comet-initiative.org/studies/details/882.
   Google Scholar